From nanoscale magnetic signals to metabolic and thermal changes, researchers are exploring how quantum sensing could give organ-on-a-chip systems a closer view of biology as it unfolds.
Paper: Integration of quantum biosensors into microfluidic organ-on-a-chip platforms toward real-time high-resolution biomedical monitoring. AI-generated abstract conceptual image created using ChatGPT/OpenAI
A recent perspective article published in the journal Next Nanotechnology examined the proposed direct integration of quantum biosensors into microfluidic organ-on-a-chip (OoC) platforms to enable high-resolution, real-time biomedical monitoring.
Microfluidic OoC Platform Limitations
Microfluidic OoC platforms are microfabricated systems comprising perfused microchannels that support living organoids or cells under dynamic flow conditions.
These platforms have gained attention as advanced microphysiological systems capable of recapitulating organ-level function and structure within precisely controlled microenvironments.
Conventional OoC platforms have limited spatial resolution, particularly within three-dimensional (3D) organoid constructs and microtissues. In microfluidic systems, traditional biosensing strategies primarily depend on intermittent sampling, endpoint biochemical assays, or fluorescent labeling.
While these approaches are effective for particular applications, they can fail to capture stochastic or transient biological events, perturb native cellular processes, and disrupt ongoing experiments.
Role of Quantum Technology
Quantum biosensors are sensing modalities that exploit spin states, excitonic effects, or quantum coherence for biological detection. For instance, atom-based magnetometers are used for ultrasensitive detection of magnetic fields, while semiconductor quantum dots are utilized for chemical and optical sensing.
These biosensors exploit quantum coherence phenomena, such as excitonic modulation in quantum dots or spin-dependent fluorescence in nitrogen-vacancy (NV) centers, to detect thermal, chemical, optical, and magnetic signals with high sensitivity.
Quantum biosensors offer an alternative to conventional sensing methods. Some of these systems can provide minimally invasive or label-free detection while preserving the native microenvironment.
The growing compatibility between quantum technologies and microfluidic architectures may enable co-localized multiparametric sensing on a single microfluidic platform, where biochemical signaling, metabolic flux, and electrophysiological activity can be monitored simultaneously.
Hybrid Quantum-OoC Systems
Hybrid quantum-OoC systems are microfluidic OoC devices with integrated quantum sensing components that are embedded at the channel or substrate level. Integrating quantum biosensors into microfluidic OoC platforms could enable multi-modal microphysiological systems to continuously monitor biological function at high resolution.
These systems could monitor across spatial scales ranging from millimeters to nanometers. Depending on the sensing modality, quantum sensors can achieve magnetic-field sensitivities approaching the picoTesla (pT) range, alongside millikelvin thermometry and single-molecule fluorescence detection.
When embedded within microfluidic channels, these devices could enable real-time monitoring of cellular activity under controlled perfusion. Microfluidic confinement can introduce optical scattering and uneven microwave fields that reduce NV sensitivity, while biological interfaces can shorten spin-relaxation times.
Combining Microfluidic OoC Systems and Quantum Biosensors
In patient-derived organoids-on-a-chip, time-varying pharmacological responses involve subtle changes in metabolic turnover, membrane potential, and ion flux. These responses can occur over milliseconds to minutes. Conventional endpoint imaging or viability assays cannot resolve such transient adaptations.
Magnetic fields produced by synchronized cardiomyocyte contractions and neuronal firing can be detected without direct electrode contact using NV-center magnetometry, which operates at ~2.87 GHz via optically detected magnetic resonance.
When photon collection efficiency is improved and coherence times exceed ∼10 µs, pT-scale magnetic fields produced by synchronized cardiomyocyte action potentials could, in principle, be resolved in cardiac-on-chip systems.
NV centers also exhibit temperature-dependent zero-field splitting, enabling thermometry at the millikelvin scale in microfluidic perfusion environments.
The author proposes that localized metabolic heating could be mapped in real time in tumor-on-chip models, provided microwave-induced heating remains within ∼1–2 °C to prevent perturbation of cellular physiology.
Quantum dot-based nanosensors (2–20 nm in diameter) can detect oxygen gradients, calcium transients, and pH fluctuations via excitonic emission shifts, enabling multiplexed biochemical investigations.
The Importance of Integration
Disease-specific microenvironments, such as ischemic injury or tumor hypoxia, exhibit localized metabolic heterogeneity and steep oxygen gradients (often >50 mmHg/mm). The insertion of conventional microsensors can perturb the local microenvironment.
Limited spatial resolution is another key constraint. Embedded functionalized quantum dots in extracellular matrices enable spatial mapping of metabolic byproducts in 3D microtissues, while surface-proximal NV centers can detect thermal or magnetic variations at the nanoscale.
Across different sensing modalities, quantum biosensors can offer subcellular spatial resolution or single-molecule sensitivity, enabling monitoring of signaling pathway activation, metabolic flux, and enzymatic kinetics at the single-cell level within complex tissues.
Quantum biosensors could help researchers quantitatively link microenvironmental stimuli to localized disease progression, cell-cell communication, and stochastic gene expression by correlating intracellular measurements with tightly controlled microfluidic gradients.
The Way Forward
The convergence of microfluidic OoC and quantum biosensing technologies could support high-resolution, physics-enabled interrogation of complex biological systems. The author argues that the translational relevance of hybrid platforms becomes clearer when quantum sensing modalities are linked to specific microfluidic OoC applications.
These systems could evolve from experimental prototypes into effective platforms for personalized therapeutic evaluation and high-content preclinical testing with continued advances in large-scale fabrication, integrated photonics, and device miniaturization.
The paper also identifies optical and microwave delivery, thermal management, multiplexed signal processing, and machine-learning requirements as engineering challenges that still need to be addressed.
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.